These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22038317)

  • 1. The role of biologics in treatment of ANCA-associated vasculitis.
    Dharmapalaiah C; Watts RA
    Mod Rheumatol; 2012 Jun; 22(3):319-26. PubMed ID: 22038317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S3. Rituximab for ANCA-associated vasculitides: the French experience.
    Charles P; Guillevin L
    Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
    [No Abstract]   [Full Text] [Related]  

  • 6. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kallenberg CG; Hauser T
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
    Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U
    Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologic therapies in the systemic vasculitides].
    Díaz-Orta MA; Rojas-Serrano J
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S33-6. PubMed ID: 22152288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for ANCA-associated vasculitides.
    Guillevin L
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Schönermarck U; Rau S; Fischereder M
    N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083401
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Hebert LA; Ardoin S; Shim RL
    N Engl J Med; 2010 Nov; 363(21):2072-3; author reply 2073-4. PubMed ID: 21083399
    [No Abstract]   [Full Text] [Related]  

  • 17. [Biological treatment options for Graves' ophthalmopathy].
    El Fassi D; Nielsen CH; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rituximab to treat ANCA-associated vasculitis].
    Guillevin L; Mahr A
    Rev Med Interne; 2011 Oct; 32(10):591-3. PubMed ID: 21872370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.